Difference between revisions of "POEMS syndrome"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !Study !Evidence |-" to "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 50%"|Study !style="width: 50%"|Evidence |-")
Line 16: Line 16:
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 +
 +
=Guidelines=
 +
==EMN==
 +
*'''2018:''' Gavriatopoulou et al. [https://www.nature.com/articles/s41375-018-0209-7 European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias] [https://www.ncbi.nlm.nih.gov/pubmed/30038381 PubMed]
  
 
=All lines of therapy=
 
=All lines of therapy=

Revision as of 16:17, 7 September 2018


Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Section editor
Headshot Cowan.jpg
Andrew J. Cowan, MD
Seattle, WA

LinkedIn

POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes

1 regimens on this page
1 variants on this page


Guidelines

EMN

All lines of therapy

RD

back to top

RD: Revlimid (Lenalidomide) & Dexamethasone

Regimen

Study Evidence
Nozza et al. 2017 Phase II, <20 pts

Chemotherapy

Supportive medications

Monthly cycles, continued until progression or excess toxicity

References

  1. Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article contains verified protocol PubMed